Join to access to all OVN content. Join for Free
Utilizing Social Media and Digital Tools in Medical Affairs
MSL effectiveness digital tools social media guidelines KOL engagement thought leadership

Utilizing Social Media and Digital Tools in Medical Affairs


Share This Article


Summary

In this episode, Tom Caravela hosts Amanda Lally to explore the growing impact of digital tools and social media in medical affairs. Amanda shares insights on leveraging social media for MSL effectiveness, greater KOL engagement, and improved insights. They discuss digital tools, social media guidelines and ethical considerations as well as strategic best practices. The episode emphasizes thought leadership, overcoming digital engagement challenges, and collaborative knowledge sharing. Amanda and Tom offer strategies for resource discovery and content sharing, encouraging listeners to embrace digital tools for future success.

Key Points

  • MSLs can leverage social media and digital tools for education on treatment landscapes, industry news, and improving daily efficiency.
  • Using AI tools like ChatGPT can help MSLs simplify complex clinical trial analyses and draft concise communication.
  • Understanding company policies on social media and AI usage is crucial to ensure compliance and maintain confidentiality.

Click for Source
MSL effectiveness, digital tools, social media guidelines, KOL engagement, thought leadership

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Podcast
The Power of Non Traditional KOL Engagement
Partner Avatar MSL Talk: Tom Caravela, Lindsey Harrer

The Power of Non Traditional KOL Engagement

Podcast
It Can be Lonely in the Life of an MSL
Partner Avatar MSL Talk: Tom Caravela, Trish Gorecki

It Can be Lonely in the Life of an MSL

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Explore OVN